Changes in Hong Kong stocks | Weilizhibo-B (09887) rose more than 6% in the morning PD-L1/4-1BB Dual Antibody WCLC updates key data LBL-024 and will soon be listed domestically

The Zhitong Finance App learned that Weilizhibo-B (09887) rose more than 6% in the morning. As of press release, it had risen 5.73% to HK$57.2, with a turnover of HK$103 million.

^{On the news, at the 2026 World Lung Cancer Conference (WCLC 2026), Weilizhibo-B announced the updated phase II clinical study data on first-line treatment of patients with non-small cell lung cancer (NSCLC) with the self-developed drug Velisin® (opatisumimab, PD-L1/4-1BB) combined with chemotherapy on the first-line treatment of patients with non-small cell lung cancer (NSCLC) in the form of an oral report.} According to the updated data, an unprecedented high remission rate was shown, and almost consistent clinical benefits were observed in patients with squamous NSCLC PD-L1 negative (PD-L1 tumor ratio score (TPS) < 1%) and positive (PD-L1 TPS ≥ 1%), while patients with non-squamous NSCLC PD-L1 TPS ≥ 1% received deep and long-lasting tumor remission.

Currently, Verisign ^® has carried out clinical studies for 14 indications, including 1 single-arm critical registration clinical study, 1 confirmatory phase III clinical study, and 9 proof-of-concept studies, covering multiple major cancer types and “cold tumors”. China Post Securities pointed out that LBL-024 will soon be listed domestically, and the academic conference will update key indication data. The NDA application for PD-L1/4-1bb double antibody LBL-024 for back-line EP-NEC has been accepted and included in priority review. It is expected that 27H1 will be approved for listing. The company has begun BD-related work in August. The 1L EP-NEC Confirmatory Phase III trial for combination chemotherapy is expected to start enrolling 26H2, and phase IB/II trial data will be announced in ESMO2026.